Humana Inc (NYSE:HUM) has earned an average rating of “Buy” from the twenty-two research firms that are covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $269.17.
Several analysts have recently weighed in on HUM shares. Jefferies Group raised shares of Humana from a “hold” rating to a “buy” rating and set a $221.00 price target for the company in a research note on Friday, January 12th. Cantor Fitzgerald reissued a “hold” rating and issued a $230.00 price target on shares of Humana in a research note on Tuesday, December 5th. Zacks Investment Research cut shares of Humana from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 19th. Credit Suisse Group raised shares of Humana from a “neutral” rating to an “outperform” rating and dropped their price target for the company from $264.90 to $246.00 in a research note on Thursday, February 8th. Finally, Deutsche Bank increased their price target on shares of Humana from $259.00 to $270.00 and gave the company a “hold” rating in a research note on Friday, February 9th.
Shares of HUM stock opened at $273.60 on Wednesday. Humana has a one year low of $203.48 and a one year high of $293.35. The stock has a market cap of $37,172.01, a PE ratio of 16.40, a P/E/G ratio of 1.46 and a beta of 0.95. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.85 and a current ratio of 1.85.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, beating the consensus estimate of $2.00 by $0.06. Humana had a net margin of 4.55% and a return on equity of 16.13%. The business had revenue of $13.19 billion during the quarter, compared to analysts’ expectations of $13.14 billion. During the same quarter in the prior year, the company posted $2.34 EPS. The business’s revenue for the quarter was up 2.4% on a year-over-year basis. equities analysts expect that Humana will post 13.84 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be given a dividend of $0.50 per share. The ex-dividend date is Wednesday, March 28th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.73%. This is a boost from Humana’s previous quarterly dividend of $0.40. Humana’s dividend payout ratio (DPR) is presently 9.59%.
Humana declared that its board has authorized a share buyback program on Thursday, December 14th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the insurance provider to buy shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its stock is undervalued.
In related news, SVP Brian P. Leclaire sold 1,679 shares of the stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $245.97, for a total transaction of $412,983.63. Following the completion of the transaction, the senior vice president now owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider M Todoroff Christopher sold 16,389 shares of the stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $273.37, for a total transaction of $4,480,260.93. Following the transaction, the insider now directly owns 13,447 shares of the company’s stock, valued at approximately $3,676,006.39. The disclosure for this sale can be found here. Insiders have sold a total of 33,339 shares of company stock valued at $9,081,201 in the last ninety days. 0.60% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the stock. Certified Advisory Corp acquired a new stake in Humana during the 4th quarter worth approximately $109,000. Fieldpoint Private Securities LLC acquired a new stake in Humana during the 3rd quarter worth approximately $115,000. American Beacon Advisors Inc. acquired a new stake in Humana during the 4th quarter worth approximately $122,000. ClariVest Asset Management LLC acquired a new stake in Humana during the 3rd quarter worth approximately $144,000. Finally, YorkBridge Wealth Partners LLC lifted its holdings in Humana by 99.0% during the 4th quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock worth $159,000 after buying an additional 297 shares in the last quarter. 96.36% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Humana Inc (HUM) Receives Average Recommendation of “Buy” from Analysts” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/21/humana-inc-hum-receives-average-recommendation-of-buy-from-analysts.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.